Carl Cummings 4/17/26 Carl Cummings 4/17/26

OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform

Carl Cummings 1/6/26 Carl Cummings 1/6/26

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate

Carl Cummings 11/17/25 Carl Cummings 11/17/25

OncoNano Announces Appointment of Brent Sorrells as Chief Operating Officer

Carl Cummings 10/27/25 Carl Cummings 10/27/25

OncoNano Medicine Presents First-in-Human Data Demonstrating Safety and Early Signs of Clinical Activity of ONM-501, a Dual-Acting STING Agonist, at AACR-NCI-EORTC

Carl Cummings 10/15/25 Carl Cummings 10/15/25

OncoNano Medicine Announces Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MacDougall Creative 5/30/24 MacDougall Creative 5/30/24

OncoNano Medicine To Present a Trials in Progress Poster for ONM-501 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

MacDougall Creative 4/10/24 MacDougall Creative 4/10/24

OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024

MacDougall Creative 3/6/24 MacDougall Creative 3/6/24

OncoNano Medicine to Present Late-Breaking Poster at the American Association for Cancer Research (AACR) Annual Meeting 2024

MacDougall Creative 3/1/24 MacDougall Creative 3/1/24

OncoNano Medicine Appoints Kartik Krishnan as Chief Executive Officer and Promotes Melissa Paoloni to Chief Operating Officer

MacDougall Creative 11/27/23 MacDougall Creative 11/27/23

OncoNano Medicine Announces First Patient Dosed in Phase 1 Study Evaluating ONM-501 in Patients with Advanced Solid Tumors and Lymphomas

MacDougall Creative 11/6/23 MacDougall Creative 11/6/23

OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research & Development

MacDougall Creative 11/3/23 MacDougall Creative 11/3/23

OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting

MacDougall Creative 10/17/23 MacDougall Creative 10/17/23

OncoNano Medicine to Present Preclinical Data for ON-BOARD™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

MacDougall Creative 9/6/23 MacDougall Creative 9/6/23

OncoNano and Regeneron Enter into Clinical Trial Supply Agreement for Use of Libtayo® (cemiplimab) in ONM-501 Study

MacDougall Creative 5/31/23 MacDougall Creative 5/31/23

OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation at 2023 ASCO Annual Meeting

MacDougall Creative 4/27/23 MacDougall Creative 4/27/23

OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

MacDougall Creative 4/18/23 MacDougall Creative 4/18/23

OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR Annual Meeting 2023

MacDougall Creative 3/27/23 MacDougall Creative 3/27/23

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

MacDougall Creative 3/16/23 MacDougall Creative 3/16/23

OncoNano Medicine to Present at the American Association for Cancer Research (AACR) Annual Meeting 2023

MacDougall Creative 1/4/23 MacDougall Creative 1/4/23

OncoNano Medicine’s Pegsitacianine Granted Breakthrough Therapy Designation for Real-Time Surgical Imaging by the Food and Drug Administration

Press Releases